CD8A and urinary bladder cancer: Although PPARγ/RXRα status was not correlated with mutation burden in bladder cancer (Supplementary Fig. 15c), there is a significant anti-correlation with CD8+ T-cell infiltration across four independent cohorts of clinical samples (Fig. 4, Supplementary Fig. 18), suggesting that PPARγ/RXRα could serve as an independent marker of immuno-phenotype and responsiveness to immunotherapy.